Repligen Corporation (RGEN)
NASDAQ: RGEN · Real-Time Price · USD
148.59
+9.08 (6.51%)
At close: Nov 12, 2024, 4:00 PM
145.00
-3.59 (-2.42%)
After-hours: Nov 12, 2024, 4:35 PM EST
Repligen Revenue
Repligen had revenue of $154.87M in the quarter ending September 30, 2024, with 9.69% growth. This brings the company's revenue in the last twelve months to $639.92M, down -4.46% year-over-year. In the year 2023, Repligen had annual revenue of $638.76M, down -20.31%.
Revenue (ttm)
$639.92M
Revenue Growth
-4.46%
P/S Ratio
12.97
Revenue / Employee
$358,898
Employees
1,783
Market Cap
8.32B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 638.76M | -162.77M | -20.31% |
Dec 31, 2022 | 801.54M | 131.00M | 19.54% |
Dec 31, 2021 | 670.53M | 304.27M | 83.08% |
Dec 31, 2020 | 366.26M | 96.02M | 35.53% |
Dec 31, 2019 | 270.25M | 76.21M | 39.28% |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Dec 31, 2014 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Walgreens Boots Alliance | 147.66B |
Henry Schein | 12.50B |
The Ensign Group | 4.11B |
Chemed | 2.38B |
Masimo | 2.04B |
HealthEquity | 1.10B |
Halozyme Therapeutics | 947.36M |
Glaukos | 360.35M |
RGEN News
- 16 hours ago - Repligen Corporation (RGEN) Q3 2024 Earnings Call Transcript - Seeking Alpha
- 18 hours ago - Repligen Q3 Earnings Beat Expectations, Highlights Improving Market Conditions, Analyst Says Well-Positioned For Long-Term Growth - Benzinga
- 1 day ago - Repligen Corporation's Earnings Preview: Expensive With Mixed Growth Prospects - Seeking Alpha
- 7 days ago - Repligen Corporation to Present at Upcoming Investor Conferences - GlobeNewsWire
- 4 weeks ago - Peptide Therapeutics Industry Report 2024, Featuring Profiles of 30+ Leading Players Including PeptiDream, PolyPeptide, Repligen, X-GEN Pharmaceuticals, Zydus Cadila and More - GlobeNewsWire
- 7 weeks ago - Repligen Opens Training & Innovation Center to Elevate Customer Experience - GlobeNewsWire
- 2 months ago - Repligen Corporation to Present at Wells Fargo Healthcare Conference - GlobeNewsWire
- 3 months ago - Exclusive: Repligen in bid for reagent vendor Maravai, sources say - Reuters